RET and non-small cell lung carcinoma: The brain is a common metastasis site in NSCLC,10 and nearly half of RET fusion-positive NSCLC patients will experience central nervous system (CNS) metastases in their lifetime.10–12 This underscores the clinical need for CNS-penetrable compounds to develop the next generation of RET TKIs.